Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Multiple Myeloma through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 36 active trials
25 drugs · 1,009 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tazemetostat | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 18, 2022 |
| Tucatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 23, 2018 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 12 | 0 | — | — | 2000-06 |
| Gemcitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2006-05 |
| Ipilimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2003-04 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2002-03 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2012-03 |
| Bevacizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2006-05 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | Jan 11, 2016 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2008-06 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2003-06 |
| Cabozantinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2012-06 |
| Clofarabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2005-03 |
| Dinaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-08 |
| Acalabrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 20, 2014 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-09 |
| Atezolizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Feb 10, 2017 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-11 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 5, 2015 |
| Leucovorin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2000-02 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 5, 2012 |
| Pentostatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 8, 2000 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Topotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jun 2, 1998 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-05 |
| Alisertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 11, 2008 |
| Belinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-01 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 15, 2019 |
| Hematopoietic Cell Transplantation | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-10 |
| Meloxicam | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-10 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 15, 2019 |
| Pasireotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-12 |
| Pralatrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-08 |
| Sonidegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 17, 2014 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-11 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-01 |
| Amrubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-08 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 17, 2019 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 12, 2012 |
| Chloroquine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-10 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 27, 2015 |
| Encorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-06 |
| Enzastaurin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-07 |
| Idarubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-08 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 15, 2019 |
| Luminespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-07 |
| Mirdametinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 1, 2026 |
| Onatasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 20, 2010 |
| Pemigatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 27, 2015 |
| Retifanlimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 27, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.